MASI

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Masimo Corp

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.
CEO
Joe Kiani
Employees
2000
Headquarters

52 Discovery
Irvine, California 92618-3105
Phone: 19492977000
www.masimo.com

News

Proxy advisors back Politan nominees for Masimo board change
Jul 15, 2024 18:45pm

https://www.investing.com/news/company-news/proxy-advisors-back-politan-nominees-for-masimo-board-change-93CH-3519654


Source:Investing.com
Leading Proxy Advisory Firm ISS Recommends Masimo Shareholders Vote FOR Both of Politan’s Director Nominees
Jul 15, 2024 18:35pm

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended shareholders vote FOR the election of Politan’s nominees, Darlene Solomon and Bill Jellison, to the Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
ISS recommends Masimo investors elect activist Politan candidates to board
Jul 15, 2024 18:05pm

https://www.investing.com/news/stock-market-news/iss-recommends-masimo-investors-elect-activist-politan-candidates-to-board-3519634


Source:Investing.com
Masimo investors should elect Politan board nominees: Glass Lewis
Jul 12, 2024 16:37pm

Masimo (MASI) stock gains as Glass Lewis recommends its shareholders vote for Politan''s board candidates. Read more here.


Source:Seeking Alpha
Leading Proxy Advisory Firm Glass Lewis Recommends Masimo Shareholders Vote FOR Both of Politan''s Director Nominees
Jul 12, 2024 15:40pm

https://www.investing.com/news/press-releases/leading-proxy-advisory-firm-glass-lewis-recommends-masimo-shareholders-vote-for-both-of-politans-director-nominees-93CH-3517713


Source:Investing.com
Leading Proxy Advisory Firm Glass Lewis Recommends Masimo Shareholders Vote FOR Both of Politan’s Director Nominees
Jul 12, 2024 15:28pm

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended shareholders vote FOR the election of Politan’s nominees, Darlene Solomon and Bill Jellison, to the Company’s Board of Directors Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Glass Lewis recommends Masimo investors elect Politan candidates to board
Jul 12, 2024 13:53pm

Proxy advisory firm Glass Lewis recommends that Masimo shareholders elect activist investor Politan''s two proposed candidates to the medical device maker''s five-member board, according to a report reviewed by Reuters.


Source:Reuters
Masimo director Brennan urges election of Politan-backed nominees
Jul 11, 2024 22:42pm

No summary available.


Source:Seeking Alpha
Masimo Q2 Preliminary Revenue Improves
Jul 09, 2024 19:47pm

Masimo Corp. (MASI), a healthcare technology company, announced a rise in its preliminary second-quarter revenue on Tuesday, exceeding analysts'' expectations. For the second quarter, the company anticipates revenue of approximately $496 million, marking a 9 percent increase compared to the same period last year. According to an average estimate from seven analysts surveyed by Thomson Reuters, revenue for the quarter was expected to be $493.56 million. Analysts'' forecasts typically exclude special items. Revenue from the Healthcare segment is projected to reach around $344 million, reflecting a 22 percent increase from the previous year. Joe Kiani, CEO of Masimo, stated, "We are excited to see the growth and strength of our healthcare business in the second quarter, combined with a very strong order backlog as we enter the third quarter. Sensor utilization and hospital census have meaningfully improved from last year." The material has been provided by InstaForex Company - www.instaforex.


Source:InstaForex